(Total Views: 454)
Posted On: 03/23/2019 11:48:34 PM
Post# of 15624
On 9/21/2009 OWCP sold for $11.00 a share, I know nothing about it at that time, but looked at the max graph of prices, and there it was. I also looked at PSTI, which I recently purchased and found it did reverse splits several years ago, and at one time adjusted for splits sold for a few hundred dollars.
I bring this up as the R/S may have been required for the survival of the company, but shareholders certainly have gotten killed unless they substantially averaged down. I can understand PSTI doing it to remain on the Nasdaq, which they apparently achieved. We're not on the Nasdaq, I don't believe a severe R/S is the correct way of getting there.
In the recent past the company has demonstrated the ability to gain funding while priced below $1. Certainly we'd all like to be above $1, but the right way to get there is by growing the value of the stock. With 150 millions shares issued, the O/S isn't unreasonably high. I believe if they call off the drastic R/S the share price will return to the $.10 to $.25 range, it could double from there with patent approvals, and it could double or better again on proof of efficacy in any patented product. That could put us at a dollar or more. Certainly I expect their could be dilution in the year or so required for this to happen, so at that point a 1 for 2 bringing the O/S to under 100 million shares might be a consideration that I believe investors could get behind. Then, with just a little more success in the clinic, or a decision that a product is worthy of bringing to market, the company could qualify for the Nasdaq. It's also very possible that after patent approval and proof of concept in early stage trials a B/P could partner which almost immediately would probably bring it to the Nasdaq.
Let's achieve the Nasdaq in a proper manner, not on the back of investors, then if at some point an R/S is needed to sustain it, I believe it could get support.
Gary
I bring this up as the R/S may have been required for the survival of the company, but shareholders certainly have gotten killed unless they substantially averaged down. I can understand PSTI doing it to remain on the Nasdaq, which they apparently achieved. We're not on the Nasdaq, I don't believe a severe R/S is the correct way of getting there.
In the recent past the company has demonstrated the ability to gain funding while priced below $1. Certainly we'd all like to be above $1, but the right way to get there is by growing the value of the stock. With 150 millions shares issued, the O/S isn't unreasonably high. I believe if they call off the drastic R/S the share price will return to the $.10 to $.25 range, it could double from there with patent approvals, and it could double or better again on proof of efficacy in any patented product. That could put us at a dollar or more. Certainly I expect their could be dilution in the year or so required for this to happen, so at that point a 1 for 2 bringing the O/S to under 100 million shares might be a consideration that I believe investors could get behind. Then, with just a little more success in the clinic, or a decision that a product is worthy of bringing to market, the company could qualify for the Nasdaq. It's also very possible that after patent approval and proof of concept in early stage trials a B/P could partner which almost immediately would probably bring it to the Nasdaq.
Let's achieve the Nasdaq in a proper manner, not on the back of investors, then if at some point an R/S is needed to sustain it, I believe it could get support.
Gary
(1)
(1)
